121 results about "Metastatic tumor" patented technology

The embodiment of the invention discloses a spinal metastatic tumor treatment scheme generation system. According to one specific embodiment, the system comprises a data processing server, an information fusion server and a scheme generation server which are in communication connection with one another, and the data processing server is used for preprocessing multi-source patient data to obtain standard multi-source patient data; the information fusion server is used for executing the following steps: performing feature code fusion on standard multi-source patient data to obtain a multi-source patient feature vector; performing feature enhancement on the multi-source patient feature vector to obtain a joint patient characterization vector; generating an initial therapeutic schedule result based on the joint patient characterization vector; and the scheme generation server is used for performing feature decision processing on the initial treatment scheme result to obtain a final treatment report. According to the embodiment, waste of computing resources can be reduced, and system response time can be shortened.

The invention discloses application of MUC12 gene in preparation of drugs for reducing rectal cancer liver metastasis, and belongs to the technical field of medical biology. According to the invention, the clear relation between colorectal cancer liver metastasis and fructose metabolism reprogramming is revealed from a molecular mechanism for the first time. The invention provides a brand-new therapeutic target and strategy by determining the brand-new transfer promoting factor MUC12 and the mediated fructose metabolism regulation effect thereof. Different from the traditional therapy only aiming at the strategies of tumor cell proliferation, blood supply and the like, the method disclosed by the invention intervenes aiming at a tumor nutrition metabolic pathway, and can weaken the metabolic adaptation and proliferation capacity of metastatic tumor cells in the liver more specifically. Experimental results show that the functions of targeted inhibition of MUC12 or downstream fructose metabolism key enzymes KHK and ALDOB thereof can significantly reduce the invasion and metastasis ability of tumor cells, and at the same time, normal growth of primary tumors cannot be significantly affected.

The invention aims to provide a preparation method and application of a metal-organic nano complex for combined treatment of tumors, belongs to the technical field of antitumor drugs, and adopts a one-pot method to prepare copper-quercetin nanoparticles with uniform morphology. The obtained metal organic complex CQT nanoparticles can be used for X-ray induced sensitization radiotherapy / chemical power combined treatment to promote tumor cell apoptosis, meanwhile, due to introduction of copper ions, the steady state of the copper ions in tumor cells is broken, tumor cell copper death is induced, interaction is formed between copper death and the radiotherapy biological effect, and the tumor cell apoptosis is promoted. The synergistic tumor treatment effect is realized. The novel CQT nano complex for three-in-one treatment of sensitization radiotherapy / chemodynamic therapy / copper death has the function of obviously delaying the growth speed of tumors. The system can maintain good stability and biocompatibility, provides an innovative and efficient treatment potential scheme for intractable tumors clinically lacking specific targets, and improves the long-term prognosis of early metastatic tumors.

The invention provides a preparation method of a two-dimensional nanobelt. The two-dimensional manganese risedronate nanobelt (RMn-NBs) is prepared from Mn < 2 + > and risedronate sodium by using a coordination self-assembly technology. The raw materials are cheap and easy to obtain, and the preparation process is simple, easy to operate and good in controllability. The two-dimensional risedronate manganese nanobelt can inhibit a hypoxia-inducible factor / vascular endothelial growth factor (HIF-1alpha / VEGF) through risedronate sodium so as to enhance the radiotherapy effect; meanwhile, Fenton-like reaction of Mn < 2 + > is utilized to amplify oxidative stress mediated by radiotherapy, a GMP-AMP synthetase stimulating factor (cGAS-STING) pathway of an interferon gene ring is synchronously activated, secretion of I-type interferon is promoted, ICD (immunogen cell death) is effectively induced, and the immunogen cell death rate is increased. And the effects of CD8 + T cell dependent systemic anti-tumor immunity and checkpoint blocking immunotherapy on primary and metastatic tumors are greatly enhanced. The RMn-NBs is used as a novel nanoscale in-situ radiotherapy vaccine, and has good biocompatibility and treatment effect.

The invention relates to the technical field of medicines, in particular to a composite nano vaccine and application thereof. The composite nano vaccine is prepared by coupling a natural compound with endoplasmic reticulum stress induction capability on the surface of Ga-MOF nano particles. The composite nano vaccine can significantly enhance the anti-tumor effect through a ferroptosis mechanism, an endoplasmic reticulum stress and immunogenic cell death mechanism and a cryoablation technology synergistic effect mechanism, reverses an immunosuppressed tumor microenvironment, inhibits the growth of primary tumors and distant metastatic tumors, and has a good anti-tumor effect. A brand new strategy is provided for comprehensive treatment of tumors, and the application prospect is wide.

Provided are compositions useful for the treatment and / or prevention of cancer and metastatic tumors. For example, a provided composition comprises a biodegradable scaffold or biomaterial comprising one or more nucleic acid agents that may act to themselves promote or inhibit an immunomodulatory pathway, and / or may encode a peptide which may promote or inhibit an immunomodulatory pathway. Also provided are methods of making provided compositions as well as kits containing materials to provide the same.

The invention provides a method and a device for automatically segmenting and positioning a bone metastatic tumor in a bone scanning image and a computer program. The method comprises the following steps of: reading an original image in bone scanning image data; and inputting the original image into a pre-trained bone metastasis tumor segmentation and positioning model, automatically segmenting and positioning a bone metastasis tumor focus in the original image, and outputting focus segmentation results from channels corresponding to different body parts, the bone metastatic tumor segmentation and positioning model is a single model architecture based on a convolutional neural network and an attention mechanism. The technical scheme provided by the invention has high-precision focus segmentation and positioning capability, enhanced model generalization capability and multi-task joint learning optimization performance, and the focus recall rate tested by applying the scheme reaches 90.2%, the focus accuracy reaches 84.5%, the focus position positioning accuracy reaches 98.4%, and the focus position positioning average AUC reaches 96.1%.

The invention provides a preparation method of a fragmented tumor antigen. The preparation method comprises the following steps: obtaining a tumor cell suspension; and irradiating and incubating the tumor cell suspension to prepare the fragmented tumor antigen. The preparation method is simple, low in cost and convenient to store, the fragmented tumor antigen prepared through the preparation method can remarkably inhibit tumor growth in vivo after being inoculated to an individual, tumor metastasis and relapse can also be effectively inhibited, immune memory is induced to be generated, the continuous anti-tumor effect is achieved, and the preparation method is suitable for clinical application. The control on metastatic tumors is obviously improved. The effective anti-tumor effect can be achieved in vivo when the fragmented tumor antigen prepared by the invention is independently or jointly used.

The invention belongs to the technical field of liver minimal metastatic tumor image detection, and discloses a liver minimal metastatic tumor image detection method based on an improved YOLO model. The invention provides a liver minimal metastatic tumor image detection model based on an improved YOLOV8 architecture for detecting pain points such as small size, low contrast and easy confusion with blood vessels / artifacts of liver minimal metastatic tumors, and a nested multi-scale adaptive convolution module and a low-contrast adaptive convolution module are introduced into a model backbone network. A dynamic cross-channel fusion module and a dynamic up-sampling module are designed in a neck network, a detection head structure is optimized at a detection end, a medical prior post-processing module is added, and a target detection network adaptive to a liver minimal metastatic tumor image detection scene is constructed. According to the method, accurate feature extraction, efficient multi-scale fusion and reliable detection and judgment of the liver minimal metastatic tumor are effectively realized, finally, the detection sensitivity and specificity of minimal focuses are improved, and the influence of interference factors such as vascular artifacts is reduced.

The invention discloses a matrix metalloproteinase-responsive multifunctional bionic ferritin nano material as well as a preparation method and application thereof. The method comprises the following steps: modifying melittin on the surface of a ferritin nanoparticle through a genetic engineering method, connecting by using a linker containing a matrix metalloproteinase 9 (MMP-2 / 9) restriction enzyme cutting site, expressing the obtained recombinant ferritin (SEQ ID NO: 6) in escherichia coli, and self-assembling to form the enzyme response functionalized bionic nanoparticle. According to the method, melittin can be connected to ferritin nanoparticles in series, the toxicity of melittin is remarkably reduced, and the melittin responds to matrix metalloproteinase in a tumor microenvironment so as to kill tumor cells; meanwhile, intravenous administration of melittin can be realized, and the melittin injection has a good treatment effect on in-situ and metastatic tumors.

The invention relates to a traditional Chinese medicine compound composition for inhibiting lung cancer metastasis and application thereof. The traditional Chinese medicine compound composition is prepared from the following raw material medicines in parts by weight: 40-45 parts of radix ophiopogonis, 4-8 parts of pinellia ternate, 4-8 parts of liquorice, 7-11 parts of ginseng, 4-8 parts of polished round-grained rice, 12-20 parts of Chinese dates and 18-27 parts of paris polyphylla. Compared with the prior art, the traditional Chinese medicine composition has a remarkable inhibiting effect on lung cancer metastasis, can remarkably induce lung cancer cell apoptosis and effectively inhibits proliferation and migration of lung cancer cells; animal experiments show that the traditional Chinese medicine composition not only can effectively reduce the number of mouse lung metastatic tumors, but also remarkably reduces the lung tumor metastasis load. In addition, the traditional Chinese medicine composition also remarkably increases the level of NK cells and CD8 + T cells in peripheral blood.

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, HIPKs, and / or CMGC kinases leading to inhibition of WNT signaling. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, HIPKs, and / or CMGC kinases leading to inhibition of WNT signaling, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer, acute myeloid leukemia, myelodysplastic syndrome), a viral infection (e.g., SARS-CoV-2 infection (e.g., COVID-19)), and other diseases.

The invention belongs to the field of biological catalytic materials, and particularly relates to a palladium monatomic-based biological catalyst, a biological catalytic compound thereof, a preparation method and application of the biological catalyst. The invention designs a coordination complex (Pd-Tpb) based on a palladium single atom from the beginning and finds that the coordination complex can be used as a biocatalyst with radiation-enhanced ROS (reactive oxygen species) generation activity and tumor killing performance for the first time. On the basis, Pd-Tpb is used for modifying lactobacillus probiotics, the obtained biocatalytic compound is used for biocatalysis and radiosensitization treatment, and it is found that the biocatalytic compound has the remarkably improved radiosensitization effect and has the effect of eradicating primary and metastatic tumors.

The application belongs to the field of biological catalytic materials, and particularly relates to a biological catalyst based on a palladium single atom, a biological catalytic complex thereof, and a preparation method and application thereof. A coordination complex (Pd-Tpb) based on a palladium single atom is designed from scratch, and it is found for the first time that the coordination complex can be used as a biological catalyst with ROS generation activity and tumor killing performance with radioenhancement. On this basis, the Pd-Tpb is used to modify lactobacillus probiotics, and the obtained biological catalytic complex is used for biological catalysis and radiosensitization treatment, and it is found that the biological catalytic complex has a significantly improved radiosensitization effect and has the effect of eradicating primary and metastatic tumors.

A novel localized mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in the tumor, thereby enhancing the efficacy of therapeutic agents and increasing immune cell infiltration. A miniaturized dual lumen catheter device configured to deliver an M-HIFU to a tumor, the M-HIFU not having the anatomical limitations of conventional HIFUs, and being capable of entering a primary or metastatic tumor regardless of its location.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention belongs to the field of anti-tumor compounds, and particularly relates to a preparation method of carboplatin-unsaturated fatty acid liposome, which comprises the following steps: S1, preparing lecithin into a lecithin solution; preparing unsaturated fatty acid into a fatty acid solution; preparing carboplatin into a carboplatin solution; s2, adding a lecithin solution and a fatty acid solution into an eggplant-shaped bottle, then adding chloroform or dichloromethane, uniformly mixing, and carrying out rotary evaporation to obtain a phospholipid membrane; s3, taking and preheating a carboplatin solution, adding the carboplatin solution into the phospholipid membrane after preheating, and performing ultrasonic hydration to obtain a liposome solution; s4, performing ultrasonic crushing on the liposome solution; and S5, filtering the ultrasonically crushed liposome solution to obtain the liposome. The invention also discloses an application of the carboplatin-unsaturated fatty acid liposome prepared by the preparation method in preparation of antitumor drugs. The problem that in the prior art, the curative effect and safety of a carboplatin drug are difficult to consider at the same time can be solved, and metastatic tumor cells can be effectively inhibited at low drug concentration.

The present application relates to a self-sustained release immune adjuvant suspension comprising microparticles composed of a lipid soluble immune adjuvant and a surfactant, the balance being a dispersant, wherein the lipid soluble immune adjuvant is coated with the surfactant to form the microparticles which are dispersed in the dispersant to form a suspension. The self-sustained release immune adjuvant suspension can be retained in a tumor for a long time and can maintain a sustained release property, and can also inhibit the growth of distal metastatic tumors and reduce the probability of tumor recurrence by means of an immune response. The present application further provides a preparation method for a self-sustained release immune adjuvant suspension, and use of the self-sustained release immune adjuvant suspension in a sensitizing formulation used for tumor therapies, such as, radiotherapy, chemotherapy, or thermotherapy.

The application relates to a method for establishing a MASH and a related liver cancer model by using a liver stellate cell-specific Lonp1 knockout mouse. flox / flox Mice are crossed with Lrat-2A Cre Mice to obtain mice with specific Lonp1 gene deletion in liver stellate cells. The mice do not have obvious liver abnormalities at 2 weeks old, liver fibrosis and lipid accumulation appear at 6 weeks old, cirrhosis and inflammation foci formation appear at 6 months old, and liver cancer gradually appears at 10 months old. More importantly, the mice can form a large number of large liver cancer nodules within 16 weeks under the induction of GAN diet. In addition, when melanoma cells are injected into the spleen to establish a splenic liver metastasis model, the liver stellate cell Lonp1 deletion mice show a significantly increased number of metastatic tumors. The model can effectively simulate the pathological process of MASH progressing to liver cancer, and provides a reliable tool for related mechanism research and drug development.

The invention discloses a diphosphonic acid manganese nanoparticle, a preparation method thereof and application of the diphosphonic acid manganese nanoparticle in tumor treatment. The preparation method comprises the following steps: dropwise adding a water-in-oil emulsion system of diphosphonate into a water-in-oil emulsion system of manganese ions in stirring to establish a coordination skeleton, curing by absolute ethyl alcohol, adding a certain proportion of fat material, performing vortex hydration by a film dispersion method, and extruding to pass through a film. The diphosphonic acid manganese nanoparticle is small in particle size and good in stability, and has a pH-sensitive release characteristic; the constructed nanoparticles have a remarkable immune regulation effect, and the ICD effect and the cytotoxic effect of oxaliplatin are enhanced by directly acting on tumor cells. The diphosphonic acid manganese nanoparticles cooperate with Oxp to effectively inhibit digestive tract tumor growth and distal metastatic tumors, the dosage of Oxp can be further reduced, and the diphosphonic acid manganese nanoparticles have good in-vivo safety.

To provide pH responsive compounds, micelles, and compositions useful for the detection of primary and metastatic tumor tissues.SOLUTION: There are provided a block copolymer of Formula (I), a micelle comprising one or more kinds of the block copolymer, and a pH responsive composition comprising the micelle, wherein the micelle has a pH transition point and an emission spectrum.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicine, and particularly relates to application of a TGF-beta RI inhibitor in tumor treatment and a pharmaceutical composition of the TGF-beta RI inhibitor. The invention discloses an application of a TGF-beta RI inhibitor single drug or a drug combination in tumor treatment, and the TGF-beta RI inhibitor single drug or the drug combination has a good anti-tumor activity effect, can obviously improve the health condition and the life quality of a patient, and is beneficial to be used as a treatment scheme of advanced or metastatic tumors.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

The application discloses application of tenapanol in preparation of a medicine for inhibiting tumor brain metastasis. The application targets neutrophils which are recruited in brain metastasis foci and promote tumor growth, screens out an inhibitor tenapanol for a neutrophil chemotactic receptor FPR2, inhibits the neutrophil recruitment to the brain and the subsequent promotion of tumor cell clonal growth by inhibiting the combination of the receptor and SAA1 which is specifically up-regulated in metastatic tumor cells, and thus the therapeutic effect of inhibiting the progression of intracranial lesions is achieved.

The preparation method comprises the following steps: firstly, screening out No.3 polypeptide with the most obvious tumor cell migration promoting effect from supernatant proteins of cancer-related fibroblast (CAF) cells of primary tumor lesions and metastatic tumor lesions of an ovarian cancer patient, and naming the No.3 polypeptide as POCMM1; scratch experiments confirm that the POCMM1 promotes migration of ovarian cancer cells and has concentration dependence, and further prove that the matrix factor POCMM1 promotes development of tumors and has the potential of serving as a biomarker for ovarian cancer diagnosis. The expression level of the matrix factor POCMM1 in serum of an ovarian cyst patient, an ovarian cancer patient without metastasis and an ovarian cancer patient with metastasis is subsequently detected, and compared with the expression level of the matrix factor POCMM1 in the serum of the ovarian cyst patient, the expression level of the matrix factor POCMM1 in the serum of the ovarian cancer patient is increased; the expression in serum of a metastatic ovarian cancer patient is the highest, so that the matrix factor POCMM1 can be confirmed to be used as a biomarker for ovarian cancer diagnosis.

The invention relates to the field of biological science and drug carriers, in particular to tumor microenvironment enzyme response type nano-particles, a preparation method and application thereof, and the tumor microenvironment enzyme response type nano-particles comprise at least two structural domains a which are sequences of matrix metalloproteinase substrate peptides; at least one structural domain b which is a sequence of melittin; the structural domain a is connected to the C tail end and the N tail end of the structural domain b; the tumor microenvironment enzyme response type melittin can slowly release melittin in a tumor microenvironment under enzyme response to achieve an anti-cancer effect, can also be used for preparing a nano-drug, and can deliver a ferroptosis small-molecule accelerant RSL3 to the tumor microenvironment in a targeted manner, so that the drug can infiltrate into tumor cells and induce tumor cell death, and the tumor microenvironment enzyme response type melittin has a good anti-cancer effect. The antigens in tumor cells are released, so that tumor immunotherapy and tumor metastasis treatment are realized, and the drug resistance of liver metastatic tumors is eliminated.

The present invention discloses an application of a genetically engineered bacterium VNP20009-M of attenuated Salmonella typhimurium in the preparation of a drug for preventing and treating post-metastatic cancer. The genetically engineered bacterium VNP20009-M has tumor targeting and significant effects of inhibiting metastasis and growth on cancer cells, and can be used for the preparation of a drug for preventing and treating post-metastatic tumors.

A novel localized mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing efficacy of therapeutic drugs and increasing immune cell infiltration. A miniaturized dual lumen catheter device is configured to deliver M-HIFU to tumors, eliminating the anatomical limitations of conventional HIFU and allowing access to primary or metastatic tumors regardless of their location.

Methods for screening therapeutic agents for activity against dormant cancer cells, therapeutic agents identified by the methods, and treatment methods related to the same, and methods for screening therapeutic agents for activity against microscopic metastatic tumor cancer cells, therapeutic agents identified by the methods, and treatment methods related to the same.

The invention discloses a preparation method and application of PAM-Fe (CO) 5 microspheres for magnetocaloric ablation treatment, a novel magnetocaloric microsphere is prepared through an SPG membrane emulsification method, and magnetocaloric microsphere mediated noninvasive magnetocaloric ablation treatment of HCC is carried out. A research result shows that the PAM-Fe (CO) 5MSs can effectively heat and kill tumor cells under the action of AMF, and meanwhile, the T cell immune response of an organism is activated, so that the anti-tumor effect is remarkably improved. Especially, when the compound is combined with an immune checkpoint inhibitor PD-1mAb for use, the effector function of immune cells is enhanced and the growth of distant metastatic tumors is inhibited through the displayed synergistic effect.